文献速递临床试验与 GCP

全微创锁孔食管切除术与混合食管切除术后的总体并发症:MICkey多中心随机对照试验研究方案

Overall morbidity after total minimally invasive keyhole oesophagectomy versus hybrid oesophagectomy (the MICkey trial): study protocol for a multicentre randomized controlled trial.
PubMed 文献 · Trials · 2023-03-10

MICkey试验是一项多中心随机对照优效性研究方案,计划纳入152例择期食管切除术的食管癌患者,按1:1随机分入混合食管切除术(HYBRID-E)对照组或全微创食管切除术(MIN-E)干预组。主要终点为术后30天内采用综合并发症指数(CCI)评估的总体并发症发生率,旨在回答MIN-E在总体术后并发症方面是否优于HYBRID-E这一尚未解决的问题。

要点

  • 食管癌根治性切除术(Ivor-Lewis手术)重大并发症风险高,微创技术旨在降低术后并发症。
  • MICkey试验为多中心随机对照优效性研究,计划纳入152例食管癌择期手术患者,1:1随机分组。
  • 主要终点为术后30天内综合并发症指数(CCI)评估的总体并发症,比较MIN-E与HYBRID-E。

核心结论

  • MICkey试验旨在回答全微创食管切除术(MIN-E)在总体术后并发症方面是否优于混合食管切除术(HYBRID-E)这一尚未解答的问题。

研究设计与样本

  • MICkey试验为多中心随机对照优效性研究,设两个平行研究组。
  • 计划纳入152例食管癌择期食管切除术患者,按1:1随机分配至对照组(HYBRID-E)或干预组(MIN-E)。

主要发现

  • 主要终点为术后30天内通过综合并发症指数(CCI)评估的总体术后并发症。
  • 次要结局包括特定围手术期参数以及患者报告结局和肿瘤学结局。

关键数值与推荐

  • 主要终点评估时间窗为术后30天内,评估工具为综合并发症指数(CCI)。
  • 试验注册号:DRKS00027927,U1111-1277-0214,注册日期为2022年7月4日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oesophageal cancer (EC) is the sixth leading cause of cancer death worldwide. Oesophageal resection is the only curative treatment option for EC which is frequently performed via an abdominal and right thoracic approach (Ivor-Lewis operation). This 2-cavity operation is associated with a high risk of major complications. To reduce postoperative morbidity, several minimally invasive techniques have been developed that can be broadly classified into either hybrid oesophagectomy (HYBRID-E) via laparoscopic/robotic abdominal and open thoracic surgery or total minimally invasive oesophagectomy (MIN-E). Both, HYBIRD-E and MIN-E, compare favourable to open oesophagectomy. However, there is still an evidence gap comparing HYBRID-E with MIN-E with regard to postoperative morbidity. METHODS: The MICkey trial is a multicentre randomized controlled superiority trial with two parallel study groups. A total of 152 patients with oesophageal cancer scheduled for elective oesophagectomy will be randomly assigned 1:1 to the control group (HYBRID-E) or to the intervention group (MIN-E). The primary endpoint will be overall postoperative morbidity assessed via the comprehensive complication index (CCI) within 30 days after surgery. Specific perioperative parameters, as well as patient-reported and oncological outcomes, will be analysed as secondary outcomes. DISCUSSION: The MICkey trial will address the yet unanswered question whether the total minimally invasive oesophagectomy (MIN-E) is superior to the HYBRID-E procedure regarding overall postoperative morbidity. TRIAL REGISTRATION: DRKS00027927 U1111-1277-0214. Registered on 4th July 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Klotz R, Diener MK, Schmidt T, et al. Overall morbidity after total minimally invasive keyhole oesophagectomy versus hybrid oesophagectomy (the MICkey trial): study protocol for a multicentre randomized controlled trial. Trials. 2023. PMID: 36899404. doi:10.1186/s13063-023-07134-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。